CMS Allows Part D Plans To Substitute All Biosimilars

Medicare Part D plan sponsors are now permitted to immediately substitute all FDA-approved biosimilars, not just those deemed “interchangeable” by FDA, as formulary “maintenance changes,” CMS announced as part of its final calendar year 2025 Medicare Advantage and Part D final rule Thursday (April 4). CMS says the move aims to provide plan sponsors with the flexibility needed to offer enrollees access to equally effective, more affordable options for prescription medications sooner than prior policy allowed. Leading health care improvement...